Trial Outcomes & Findings for Pentoxifylline for Acute Alcoholic Hepatitis (AAH) (NCT NCT00205049)
NCT ID: NCT00205049
Last Updated: 2014-05-13
Results Overview
Recruitment status
TERMINATED
Study phase
PHASE1
Target enrollment
4 participants
Primary outcome timeframe
28 days
Results posted on
2014-05-13
Participant Flow
Participant milestones
| Measure |
Pentoxifylline
All subjects will be randomized to receive either pentoxifylline 400mg orally or placebo 3 times daily for 28 days
|
Placebo
All subjects will be randomized to receive either pentoxifylline 400mg orally or placebo 3 times daily for 28 days
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Pentoxifylline for Acute Alcoholic Hepatitis (AAH)
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 28 daysPopulation: Study was terminated before any data was gathered/analyzed.
Outcome measures
Outcome data not reported
Adverse Events
Pentoxifylline
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Placebo
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Research Program Manager - Kelly Richie
University of Wisconsin
Phone: 608-262-5404
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place